Themis Medicare Reports Q4 Profit Turnaround, Full Year Revenue Slips

Consolidated Q4 FY26 Net Profit: ₹8.89 crore
Consolidated FY26 Revenue: ₹342.24 crore

Reader Takeaway: Quarterly profit turnaround is positive; full-year revenue decline and thin margins are key concerns.

What just happened

Themis Medicare Ltd announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a consolidated net profit after tax (PAT) of ₹8.89 crore for Q4 FY26, a significant turnaround from a net loss of ₹9.66 crore in Q4 FY25. Revenue from operations for the quarter grew by 6.7% year-on-year to ₹76.53 crore.

However, the full-year financial performance for FY26 showed a decline. Consolidated revenue for the fiscal year was ₹342.24 crore, down 15.6% from ₹405.51 crore in FY25. The net profit for FY26 stood at ₹1.14 crore, a sharp decrease from ₹29.83 crore in the previous fiscal year. EBITDA for FY26 was ₹0.39 crore, a significant drop from ₹49.05 crore in FY25.

Why this matters

The quarterly turnaround in profitability is a positive signal for investors, indicating improved operational efficiency and cost management during the period. The strategic shift towards the Hospital segment, which now contributes 50% of the revenue, is a key development. However, the overall decline in full-year revenue and profit, coupled with drastically reduced margins (EBITDA margin at 0.11% for FY26), raises concerns about the company's sustained performance and operational health.

The backstory

Themis Medicare has been undergoing strategic changes, focusing on optimizing its business mix. The company's performance in recent quarters has shown volatility, with efforts to boost profitability amidst challenging market conditions in segments like Formulations. The shift in revenue contribution towards the Hospital segment highlights a strategic pivot aimed at stabilizing and growing its top line.

What changes now

Investors will be closely watching the company's ability to sustain the quarterly profit trend in the upcoming quarters. The focus will be on the successful restructuring of the Formulation segment and the continued growth and profitability of the Hospital segment. Management's emphasis on productivity and efficiency will be crucial for navigating operational challenges and improving margins.

Risks to watch

Key risks include the continued softness in the Formulations segment, the ability to maintain operational efficiency and cost controls, and the thin EBITDA margins for the full year, which offer little buffer against unforeseen challenges. The sustainability of the Hospital segment's contribution also needs to be monitored.

Peer comparison

[Grounded search for peer comparison data is unavailable or unreliable.]

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹76.53 crore (Up 6.7% YoY)
• Q4 FY26 PAT: ₹8.89 crore (Turnaround from loss)
• FY26 Revenue: ₹342.24 crore (Down 15.6% YoY)
• FY26 PAT: ₹1.14 crore (Down 96.2% YoY)
• FY26 EBITDA Margin: 0.11% (vs. 12.10% in FY25)
• Hospital Segment Contribution: 50% of FY26 Revenue (vs. 38% in FY25)

What to track next

Investors should monitor the progress of the Formulations segment's restructuring, the sustained revenue growth from the Hospital segment, and overall margin improvement in future financial reports.